Immunovant, Inc. today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, emphasizing a strengthened cash position and continued advancement of its IMVT-1402 pipeline. For the fiscal year 2025, the company reported a net loss of $413.8 million, or $2.73 per common share, compared to a net loss of $259.3 million, or $1.88 per common share, in fiscal year 2024. Research and development expenses increased to $360.9 million from $212.9 million year-over-year, primarily due to IMVT-1402 clinical trials and batoclimab pivotal trials.
As of March 31, 2025, Immunovant's cash and cash equivalents totaled approximately $714 million. This substantial liquidity is expected to fund operating expenses and capital expenditure requirements for announced indications through the Graves' Disease readout, anticipated in 2027. This financial runway provides stability for the company's aggressive clinical development strategy.
The IMVT-1402 program is actively progressing across six announced indications, including potentially registrational trials in Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and Sjögren’s disease (SjD), as well as a proof-of-concept trial in cutaneous lupus erythematosus (CLE). The company plans to initiate a potentially registrational trial for SjD and a second potentially registrational trial for GD in the summer of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.